Propanc Biopharma Receives Investment from Institutional Investor
07/28/20, 12:35 PM
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the company received an additional investment tranche from a lead institutional investor to support company operations and working capital needs. To date, a, total of $550,000 has been funded by the institutional investor of a $3,000,000 financing agreement, as the company prepares its lead product candidate, PRP, for a Phase IB, First-In-Human study, in advanced cancer patients suffering from solid tumors.
Company Info
Additional Info
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.